Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
760 USD | -1.50% | +3.41% | +30.38% |
May. 10 | Cipla Open to Partner With Eli Lilly to Market Obesity Drugs in India | MT |
May. 10 | Roughly 1 in 8 US adults have taken GLP-1 drugs like Wegovy, poll shows | RE |
Evolution of the average Target Price on Eli Lilly and Company
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Eli Lilly and Company
China International Capital | |
JPMorgan Chase | |
Wolfe Research | |
Barclays | |
BMO Capital | |
Leerink Partners | |
Deutsche Bank Securities | |
Truist Securities | |
Goldman Sachs | |
Wells Fargo Securities | |
Morgan Stanley | |
Jefferies & Co. | |
UBS | |
BofA Securities | |
DZ Bank | |
JEFFERIES | Akash Tewari |
Cantor Fitzgerald | |
Morningstar | |
Guggenheim | |
Daiwa Securities | |
Berenberg Bank | |
Citigroup | |
Argus | |
Credit Suisse | |
HSBC | |
TD Cowen | |
SVB Securities LLC | |
Cowen | |
Mizuho Securities |
EPS Revisions
- Stock Market
- Equities
- LLY Stock
- Consensus Eli Lilly and Company